Evidence map›Paper›PMID 20161703›Full record

ArticlePloS one2010

Extracellular BCL2 proteins are danger-associated molecular patterns that reduce tissue damage in murine models of ischemia-reperfusion injury.

Akiko Iwata, Vicki Morgan-Stevenson, Barbara Schwartz, Li Liu, Joan Tupper, Xiaodong Zhu, John Harlan, Robert Winn

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Activation of immune signals during organ transplantation.Signal transduction and targeted therapy · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Gender disparity in the role of TLR2 in post-ischemic myocardial inflammation and injury.International journal of clinical and experimental medicine · 2015
    Article
  11. Article
  12. Article
  13. Review
  14. Dangers within: DAMP responses to damage and cell death in kidney disease.Journal of the American Society of Nephrology : JASN · 2011
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Akiko IwataDepartment of Surgery, University of Washington, Seattle, Washington, United States of America.
Vicki Morgan-Stevenson
Barbara Schwartz
Li Liu
Joan Tupper
Xiaodong Zhu
John Harlan
Robert Winn
University of Washington · US

Funding

Neovasculature, Plaque Rupture And Progression by MRIP01HL072262 · NHLBI · UNIVERSITY OF WASHINGTON · PI SCHWARTZ, STEPHEN MARK · 2002 to 2006
$11.5M
NEUTROPHILS IN ISCHEMIA REPERFUSION INJURY IN SHOCKR01GM042686 · NIGMS · UNIVERSITY OF WASHINGTON · PI HARLAN, JOHN MARSHALL · 1990 to 2009
$2.0M
The Role of Bcl-2 in Ischemia-Reperfusion InjuryR01GM066197 · NIGMS · UNIVERSITY OF WASHINGTON · PI WINN, ROBERT K · 2003 to 2006
$1.2M
Endothelial Toll-Like Receptor-4 Signaling in SepsisR01GM071398 · NIGMS · UNIVERSITY OF WASHINGTON · PI HARLAN, JOHN MARSHALL · 2005 to 2008
$881k
NHLBI NIH HHS HL72262NHLBI NIH HHS P01 HL072262NIGMS NIH HHS GM071398NIGMS NIH HHS GM42686NIGMS NIH HHS GM66197NIGMS NIH HHS R01 GM042686NIGMS NIH HHS R01 GM066197NIGMS NIH HHS R01 GM071398
6 · The paper itself

Abstract

backgroundIschemia-reperfusion (I/R) injury contributes to organ dysfunction in a variety of clinical disorders, including myocardial infarction, stroke, organ transplantation, and hemorrhagic shock. Recent investigations have demonstrated that apoptosis as an important mechanism of cell death leading to organ dysfunction following I/R. Intracellular danger-associated molecular patterns (DAMPs) released during cell death can activate cytoprotective responses by engaging receptors of the innate immune system. METHODOLOGY/PRINCIPAL

findingsIschemia was induced in the mouse hind limb by tourniquet or in the heart by coronary artery ligation. Reperfusion injury of skeletal or cardiac muscle was markedly reduced by intraperitoneal or subcutaneous injection of recombinant human (rh)BCL2 protein or rhBCL2-related protein A1 (BCL2A1) (50 ng/g) given prior to ischemia or at the time of reperfusion. The cytoprotective activity of extracellular rhBCL2 or rhBCL2A1 protein was mapped to the BH4 domain, as treatment with a mutant BCL2 protein lacking the BH4 domain was not protective, whereas peptides derived from the BH4 domain of BCL2 or the BH4-like domain of BCL2A1 were. Protection by extracellular rhBCL2 or rhBCL2A1 was associated with a reduction in apoptosis in skeletal and cardiac muscle following I/R, concomitant with increased expression of endogenous mouse BCL2 (mBCL2) protein. Notably, treatment with rhBCL2A1 protein did not protect mice deficient in toll-like receptor-2 (TLR2) or the adaptor protein, myeloid differentiation factor-88 (MyD88). CONCLUSIONS/SIGNIFICANCE: Treatment with cytokine-like doses of rhBCL2 or rhBCL2A1 protein or BH4-domain peptides reduces apoptosis and tissue injury following I/R by a TLR2-MyD88-dependent mechanism. These findings establish a novel extracellular cytoprotective activity of BCL2 BH4-domain proteins as potent cytoprotective DAMPs.

Indexed as

Disease Models, AnimalAmino Acid SequenceAnimalsApoptosisHindlimbHumansMiceMice, Inbred C57BLMice, KnockoutMinor Histocompatibility AntigensMolecular Sequence DataMuscle, SkeletalMyeloid Differentiation Factor 88Myocardial IschemiaPeptidesProto-Oncogene ProteinsBcl2 protein, mouseBCL2-related protein A1Minor Histocompatibility AntigensMyeloid Differentiation Factor 88PeptidesProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Recombinant ProteinsToll-Like Receptor 2

Identifiers

PMID20161703
PMCPMC2816997
OpenAlexW2045263516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.